Review



mcf  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC mcf
    Mcf, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 34799 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcf/MCF7/pmc13101642-75-0-9
    Average 99 stars, based on 34799 article reviews
    mcf - by Bioz Stars, 2026-09
    99/100 stars

    Images

    Related Articles

    Cell Culture:

    Article Title: Evaluation of the efficacy of rutin, rutin nanocrystals, and rutin spanlastics nanoparticles as antitumor and antioxidant drug delivery systems.
    Article Snippet: .. The MCF-7 human breast cancer model routinely utilized was obtained from the American Type Culture Collection (ATCC; USA) and cultured from the National Cancer Institute (NCI; Cairo, Egypt). .. Cells were subcultured in Dulbecco's Modified Eagle Medium (DMEM; Gibco, USA) with 10% heat-inactivated fetal bovine serum (FBS; Sigma-Aldrich, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin (Lonza, Switzerland).

    Article Title: Dual Role of Cancer Epithelial-Specific TRAF3 in Regulating Breast Cancer Cell Survival and Lymphocyte Activity
    Article Snippet: Publicly available mRNA expression data was analyzed and visualized in breast cancer cohorts through cBioPortal [ , ] (TCGA-BRCA) and the GOBO on-line tool [ ] (Chi, GSE11121 , GSE12093 , GSE2034 , GSE2603 , GSE5327 , GSE6532 , GSE7390 , GSE12093 , GSE1456 , GSE3494 , GSE7390 ) presented in detail in . .. Breast cancer cell lines MDA-MB-231 and MCF-7 were purchased from ATCC (Manassas, VA, USA) and cultured in 37 °C, 5% CO 2 , in DMEM medium with 10% FBS and pen/strep. .. The TRAF3 coding sequence was amplified from a pCMV6-TRAF3-GFP (RG210417, Origene, Rockville, MD, USA) vector and cloned into pLenti-EF1a-GFP-2A-Puro (LV067, ABM Inc, Richmond, BC, Canada).

    Modification:

    Article Title: Equilibrium and non-equilibrium thermodynamics in drug repurposing: Machine learning-guided discovery of high-affinity WEE1 kinase inhibitors.
    Article Snippet: WEE1 kinase represents a promising therapeutic target in oncology due to its critical role in cell cycle checkpoint regulation.. Traditional drug discovery for WEE1 inhibitors has been constrained by the time and resource demands of conventional screening.. Here, we integrate machine learning with equilibrium and non-equilibrium thermodynamic analyses to identify potential WEE1 inhibitors from FDA-approved drug libraries.

    Multiple Displacement Amplification:

    Article Title: Sparingly PEGylated Adipate Copolymers via Enzymatic Synthesis as Nano-Carriers for Solid Dispersions.
    Article Snippet: .. The human epithelial cell line Caco-2, the MCF-7 human breast cancer cells, and the MDA-MB-231 late-stage triple-negative breast cancer cells were obtained from the American Type Culture Collection (ATCC) and used across a 10-passage window. ..

    Article Title: Dual Role of Cancer Epithelial-Specific TRAF3 in Regulating Breast Cancer Cell Survival and Lymphocyte Activity
    Article Snippet: Publicly available mRNA expression data was analyzed and visualized in breast cancer cohorts through cBioPortal [ , ] (TCGA-BRCA) and the GOBO on-line tool [ ] (Chi, GSE11121 , GSE12093 , GSE2034 , GSE2603 , GSE5327 , GSE6532 , GSE7390 , GSE12093 , GSE1456 , GSE3494 , GSE7390 ) presented in detail in . .. Breast cancer cell lines MDA-MB-231 and MCF-7 were purchased from ATCC (Manassas, VA, USA) and cultured in 37 °C, 5% CO 2 , in DMEM medium with 10% FBS and pen/strep. .. The TRAF3 coding sequence was amplified from a pCMV6-TRAF3-GFP (RG210417, Origene, Rockville, MD, USA) vector and cloned into pLenti-EF1a-GFP-2A-Puro (LV067, ABM Inc, Richmond, BC, Canada).



    Similar Products

    mcf  (ATCC)
    99
    ATCC mcf
    Mcf, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcf/MCF7/pmc13101642-75-0-9
    Average 99 stars, based on 1 article reviews
    mcf - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    mcf  (MedChemExpress)
    94
    MedChemExpress mcf
    Micafungin-selected mutants have increased growth in all three antifungal classes, recapitulated by engineered deletions. <t>Minimum</t> <t>inhibitory</t> concentrations (MIC 50 ) determined by the static broth microdilution assay for ( A ) <t>MCF</t> (0-8 µg/mL), ( B ) FLC (0-256 µg/mL), and ( C ) by E-test for AMB (0-32 µg/mL). All MIC values available in Table S3. Replicates are indicated by gray points. ( D-F ) 96-well growth curve analysis of the in vitro evolved mutants and progenitor. Area Under the Curve (AUC) measured by OD 600 from growth curve assays in: ( D ) YPAD + 0.025 µg/mL MCF; ( E ) YPAD + 0.5 µg/mL FLC; or ( F ) YPAD. Replicates are indicated by gray points. Asterisks represent p < 0.05 relative to progenitor. Significant differences determined by ANOVA with Tukey HSD post-hoc analysis with adjustments for multiple comparisons (Table S3 for p-values). ( G-I ) Null mutants engineered in the RSY426 genetic background. AUC measured by OD 600 from growth assays in: ( G ) YPAD + 0.025 µg/mL MCF ( osh2Δ , p = 0.0001; erg3Δ , p = 0.0 ); ( H ) YPAD + 0.5 µg/mL FLC ( osh2Δ, p = 0.08; erg3Δ, p = 0.03 ); or ( I ) YPAD. Asterisks represent p < 0.05 relative to RSY426. Significant differences determined by ANOVA with Tukey HSD post-hoc analysis and adjustments for multiple comparisons (Table S3).
    Mcf, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcf/Micafungin+sodium/bio_rxiv__64898__2026__06__29__735437-238-11-12
    Average 94 stars, based on 1 article reviews
    mcf - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    mcf-7 cells  (CLS Cell Lines Service GmbH)
    95
    CLS Cell Lines Service GmbH mcf-7 cells
    Micafungin-selected mutants have increased growth in all three antifungal classes, recapitulated by engineered deletions. <t>Minimum</t> <t>inhibitory</t> concentrations (MIC 50 ) determined by the static broth microdilution assay for ( A ) <t>MCF</t> (0-8 µg/mL), ( B ) FLC (0-256 µg/mL), and ( C ) by E-test for AMB (0-32 µg/mL). All MIC values available in Table S3. Replicates are indicated by gray points. ( D-F ) 96-well growth curve analysis of the in vitro evolved mutants and progenitor. Area Under the Curve (AUC) measured by OD 600 from growth curve assays in: ( D ) YPAD + 0.025 µg/mL MCF; ( E ) YPAD + 0.5 µg/mL FLC; or ( F ) YPAD. Replicates are indicated by gray points. Asterisks represent p < 0.05 relative to progenitor. Significant differences determined by ANOVA with Tukey HSD post-hoc analysis with adjustments for multiple comparisons (Table S3 for p-values). ( G-I ) Null mutants engineered in the RSY426 genetic background. AUC measured by OD 600 from growth assays in: ( G ) YPAD + 0.025 µg/mL MCF ( osh2Δ , p = 0.0001; erg3Δ , p = 0.0 ); ( H ) YPAD + 0.5 µg/mL FLC ( osh2Δ, p = 0.08; erg3Δ, p = 0.03 ); or ( I ) YPAD. Asterisks represent p < 0.05 relative to RSY426. Significant differences determined by ANOVA with Tukey HSD post-hoc analysis and adjustments for multiple comparisons (Table S3).
    Mcf 7 Cells, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcf/MCF-7+Cells/custom%40300273%4010%2E3390%2Fph19071001
    Average 95 stars, based on 1 article reviews
    mcf-7 cells - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    human breast cancer cell line mcf 7  (ATCC)
    99
    ATCC human breast cancer cell line mcf 7
    Micafungin-selected mutants have increased growth in all three antifungal classes, recapitulated by engineered deletions. <t>Minimum</t> <t>inhibitory</t> concentrations (MIC 50 ) determined by the static broth microdilution assay for ( A ) <t>MCF</t> (0-8 µg/mL), ( B ) FLC (0-256 µg/mL), and ( C ) by E-test for AMB (0-32 µg/mL). All MIC values available in Table S3. Replicates are indicated by gray points. ( D-F ) 96-well growth curve analysis of the in vitro evolved mutants and progenitor. Area Under the Curve (AUC) measured by OD 600 from growth curve assays in: ( D ) YPAD + 0.025 µg/mL MCF; ( E ) YPAD + 0.5 µg/mL FLC; or ( F ) YPAD. Replicates are indicated by gray points. Asterisks represent p < 0.05 relative to progenitor. Significant differences determined by ANOVA with Tukey HSD post-hoc analysis with adjustments for multiple comparisons (Table S3 for p-values). ( G-I ) Null mutants engineered in the RSY426 genetic background. AUC measured by OD 600 from growth assays in: ( G ) YPAD + 0.025 µg/mL MCF ( osh2Δ , p = 0.0001; erg3Δ , p = 0.0 ); ( H ) YPAD + 0.5 µg/mL FLC ( osh2Δ, p = 0.08; erg3Δ, p = 0.03 ); or ( I ) YPAD. Asterisks represent p < 0.05 relative to RSY426. Significant differences determined by ANOVA with Tukey HSD post-hoc analysis and adjustments for multiple comparisons (Table S3).
    Human Breast Cancer Cell Line Mcf 7, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcf/MCF7/pmc13101642-243-7-13
    Average 99 stars, based on 1 article reviews
    human breast cancer cell line mcf 7 - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    mcf7  (ATCC)
    99
    ATCC mcf7
    Micafungin-selected mutants have increased growth in all three antifungal classes, recapitulated by engineered deletions. <t>Minimum</t> <t>inhibitory</t> concentrations (MIC 50 ) determined by the static broth microdilution assay for ( A ) <t>MCF</t> (0-8 µg/mL), ( B ) FLC (0-256 µg/mL), and ( C ) by E-test for AMB (0-32 µg/mL). All MIC values available in Table S3. Replicates are indicated by gray points. ( D-F ) 96-well growth curve analysis of the in vitro evolved mutants and progenitor. Area Under the Curve (AUC) measured by OD 600 from growth curve assays in: ( D ) YPAD + 0.025 µg/mL MCF; ( E ) YPAD + 0.5 µg/mL FLC; or ( F ) YPAD. Replicates are indicated by gray points. Asterisks represent p < 0.05 relative to progenitor. Significant differences determined by ANOVA with Tukey HSD post-hoc analysis with adjustments for multiple comparisons (Table S3 for p-values). ( G-I ) Null mutants engineered in the RSY426 genetic background. AUC measured by OD 600 from growth assays in: ( G ) YPAD + 0.025 µg/mL MCF ( osh2Δ , p = 0.0001; erg3Δ , p = 0.0 ); ( H ) YPAD + 0.5 µg/mL FLC ( osh2Δ, p = 0.08; erg3Δ, p = 0.03 ); or ( I ) YPAD. Asterisks represent p < 0.05 relative to RSY426. Significant differences determined by ANOVA with Tukey HSD post-hoc analysis and adjustments for multiple comparisons (Table S3).
    Mcf7, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcf/MCF7/custom%40htb-22%4042472092
    Average 99 stars, based on 1 article reviews
    mcf7 - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    mcf10a cell lines  (ATCC)
    99
    ATCC mcf10a cell lines
    Micafungin-selected mutants have increased growth in all three antifungal classes, recapitulated by engineered deletions. <t>Minimum</t> <t>inhibitory</t> concentrations (MIC 50 ) determined by the static broth microdilution assay for ( A ) <t>MCF</t> (0-8 µg/mL), ( B ) FLC (0-256 µg/mL), and ( C ) by E-test for AMB (0-32 µg/mL). All MIC values available in Table S3. Replicates are indicated by gray points. ( D-F ) 96-well growth curve analysis of the in vitro evolved mutants and progenitor. Area Under the Curve (AUC) measured by OD 600 from growth curve assays in: ( D ) YPAD + 0.025 µg/mL MCF; ( E ) YPAD + 0.5 µg/mL FLC; or ( F ) YPAD. Replicates are indicated by gray points. Asterisks represent p < 0.05 relative to progenitor. Significant differences determined by ANOVA with Tukey HSD post-hoc analysis with adjustments for multiple comparisons (Table S3 for p-values). ( G-I ) Null mutants engineered in the RSY426 genetic background. AUC measured by OD 600 from growth assays in: ( G ) YPAD + 0.025 µg/mL MCF ( osh2Δ , p = 0.0001; erg3Δ , p = 0.0 ); ( H ) YPAD + 0.5 µg/mL FLC ( osh2Δ, p = 0.08; erg3Δ, p = 0.03 ); or ( I ) YPAD. Asterisks represent p < 0.05 relative to RSY426. Significant differences determined by ANOVA with Tukey HSD post-hoc analysis and adjustments for multiple comparisons (Table S3).
    Mcf10a Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcf/MCF+10A/pm42235302-221-12-19
    Average 99 stars, based on 1 article reviews
    mcf10a cell lines - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    mcf 7  (ATCC)
    99
    ATCC mcf 7
    Experimental observations of cancer cells distributed at low and high density (A and B) Breast cancer cell <t>line</t> <t>MCF-7</t> at low and high density. (C and D) Breast cancer cell line MDA-MB-231 at low and high density. The scale bars on all panels represent 50 μm in length.
    Mcf 7, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mcf/MCF7/pmc13207371-36-0-6
    Average 99 stars, based on 1 article reviews
    mcf 7 - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Micafungin-selected mutants have increased growth in all three antifungal classes, recapitulated by engineered deletions. Minimum inhibitory concentrations (MIC 50 ) determined by the static broth microdilution assay for ( A ) MCF (0-8 µg/mL), ( B ) FLC (0-256 µg/mL), and ( C ) by E-test for AMB (0-32 µg/mL). All MIC values available in Table S3. Replicates are indicated by gray points. ( D-F ) 96-well growth curve analysis of the in vitro evolved mutants and progenitor. Area Under the Curve (AUC) measured by OD 600 from growth curve assays in: ( D ) YPAD + 0.025 µg/mL MCF; ( E ) YPAD + 0.5 µg/mL FLC; or ( F ) YPAD. Replicates are indicated by gray points. Asterisks represent p < 0.05 relative to progenitor. Significant differences determined by ANOVA with Tukey HSD post-hoc analysis with adjustments for multiple comparisons (Table S3 for p-values). ( G-I ) Null mutants engineered in the RSY426 genetic background. AUC measured by OD 600 from growth assays in: ( G ) YPAD + 0.025 µg/mL MCF ( osh2Δ , p = 0.0001; erg3Δ , p = 0.0 ); ( H ) YPAD + 0.5 µg/mL FLC ( osh2Δ, p = 0.08; erg3Δ, p = 0.03 ); or ( I ) YPAD. Asterisks represent p < 0.05 relative to RSY426. Significant differences determined by ANOVA with Tukey HSD post-hoc analysis and adjustments for multiple comparisons (Table S3).

    Journal: bioRxiv

    Article Title: Micafungin exposure drives multidrug resistance in Clavispora lusitaniae

    doi: 10.64898/2026.06.29.735437

    Figure Lengend Snippet: Micafungin-selected mutants have increased growth in all three antifungal classes, recapitulated by engineered deletions. Minimum inhibitory concentrations (MIC 50 ) determined by the static broth microdilution assay for ( A ) MCF (0-8 µg/mL), ( B ) FLC (0-256 µg/mL), and ( C ) by E-test for AMB (0-32 µg/mL). All MIC values available in Table S3. Replicates are indicated by gray points. ( D-F ) 96-well growth curve analysis of the in vitro evolved mutants and progenitor. Area Under the Curve (AUC) measured by OD 600 from growth curve assays in: ( D ) YPAD + 0.025 µg/mL MCF; ( E ) YPAD + 0.5 µg/mL FLC; or ( F ) YPAD. Replicates are indicated by gray points. Asterisks represent p < 0.05 relative to progenitor. Significant differences determined by ANOVA with Tukey HSD post-hoc analysis with adjustments for multiple comparisons (Table S3 for p-values). ( G-I ) Null mutants engineered in the RSY426 genetic background. AUC measured by OD 600 from growth assays in: ( G ) YPAD + 0.025 µg/mL MCF ( osh2Δ , p = 0.0001; erg3Δ , p = 0.0 ); ( H ) YPAD + 0.5 µg/mL FLC ( osh2Δ, p = 0.08; erg3Δ, p = 0.03 ); or ( I ) YPAD. Asterisks represent p < 0.05 relative to RSY426. Significant differences determined by ANOVA with Tukey HSD post-hoc analysis and adjustments for multiple comparisons (Table S3).

    Article Snippet: Minimum inhibitory concentration (MIC) values for both FLC (ThermoFisher; 86386-73-4) and MCF (MedChemExpress; 208538-73-2) were determined using the broth microdilution method ( ).

    Techniques: Microdilution Assay, In Vitro

    Area Under the Curve (AUC) measured by OD 600 from 48 hour growth curve assays in the presence and absence of the Hsp90 inhibitor, radicicol (RAD) for the C. lusitaniae progenitor, evolved ERG3 point mutants, and clinical isolate with ERG3 mutation. ( A ) AUC in YPAD in the absence (-) or presence (+) of 2.5 µg/mL RAD. ( B ) AUC in 0.025 µg/mL MCF in the absence (-) or presence (+) of 2.5 µg/mL RAD. ( C ) AUC in 0.5 µg/mL FLC in the absence (-) or presence (+) of 2.5 µg/mL RAD. Gray points indicate technical replicates. Significance (p < 0.05, ANOVA with Tukey HSD) indicated with asterisks or ‘n.s.’ for not significant (p ≥ 0.05) (Table S4). ( D, E ) Median fluorescence intensity of ( D ) Calcofluor white that stains chitin (10 µg/mL) or ( E ) hDectin that stains 1,3-β-D-glucans (15 µg/mL) measured by flow cytometry (n ≥ 10,000 cells per isolate per replicate). Asterisk represents p < 0.05 relative to progenitor determined by ANOVA with Tukey HSD post-hoc analysis and adjustments for multiple comparisons (Table S5). ( F ) Serial dilutions (10 6 -10 2 ) of evolved ERG3 mutants and progenitor isolate were spotted on agar plates with YPAD or YPAD + 15 µg/mL Calcofluor white, + 150 µg/mL Congo Red, or + 0.005% Sodium Dodecyl Sulfate (SDS). All plates were repeated in triplicate, incubated at 30°C and imaged at 24 hours.

    Journal: bioRxiv

    Article Title: Micafungin exposure drives multidrug resistance in Clavispora lusitaniae

    doi: 10.64898/2026.06.29.735437

    Figure Lengend Snippet: Area Under the Curve (AUC) measured by OD 600 from 48 hour growth curve assays in the presence and absence of the Hsp90 inhibitor, radicicol (RAD) for the C. lusitaniae progenitor, evolved ERG3 point mutants, and clinical isolate with ERG3 mutation. ( A ) AUC in YPAD in the absence (-) or presence (+) of 2.5 µg/mL RAD. ( B ) AUC in 0.025 µg/mL MCF in the absence (-) or presence (+) of 2.5 µg/mL RAD. ( C ) AUC in 0.5 µg/mL FLC in the absence (-) or presence (+) of 2.5 µg/mL RAD. Gray points indicate technical replicates. Significance (p < 0.05, ANOVA with Tukey HSD) indicated with asterisks or ‘n.s.’ for not significant (p ≥ 0.05) (Table S4). ( D, E ) Median fluorescence intensity of ( D ) Calcofluor white that stains chitin (10 µg/mL) or ( E ) hDectin that stains 1,3-β-D-glucans (15 µg/mL) measured by flow cytometry (n ≥ 10,000 cells per isolate per replicate). Asterisk represents p < 0.05 relative to progenitor determined by ANOVA with Tukey HSD post-hoc analysis and adjustments for multiple comparisons (Table S5). ( F ) Serial dilutions (10 6 -10 2 ) of evolved ERG3 mutants and progenitor isolate were spotted on agar plates with YPAD or YPAD + 15 µg/mL Calcofluor white, + 150 µg/mL Congo Red, or + 0.005% Sodium Dodecyl Sulfate (SDS). All plates were repeated in triplicate, incubated at 30°C and imaged at 24 hours.

    Article Snippet: Minimum inhibitory concentration (MIC) values for both FLC (ThermoFisher; 86386-73-4) and MCF (MedChemExpress; 208538-73-2) were determined using the broth microdilution method ( ).

    Techniques: Mutagenesis, Fluorescence, Flow Cytometry, Incubation

    Representative GC-MS chromatograms for the following isolates: ( A ) the drug-sensitive C. lusitaniae clinical isolate AMS5200 and progenitor for the current study ; ( B ) the in vitro evolved ERG3 A149P mutant; and ( C ) the in vitro evolved ERG3 Y304* mutant. GC-MS data obtained from cells grown for 4 hours in 0 µg/mL antifungals (No drug), 0.5 µg/mL fluconazole (FLC), or 0.016 µg/mL micafungin (MCF). Retention times indicated by values adjacent to peaks for known standards.

    Journal: bioRxiv

    Article Title: Micafungin exposure drives multidrug resistance in Clavispora lusitaniae

    doi: 10.64898/2026.06.29.735437

    Figure Lengend Snippet: Representative GC-MS chromatograms for the following isolates: ( A ) the drug-sensitive C. lusitaniae clinical isolate AMS5200 and progenitor for the current study ; ( B ) the in vitro evolved ERG3 A149P mutant; and ( C ) the in vitro evolved ERG3 Y304* mutant. GC-MS data obtained from cells grown for 4 hours in 0 µg/mL antifungals (No drug), 0.5 µg/mL fluconazole (FLC), or 0.016 µg/mL micafungin (MCF). Retention times indicated by values adjacent to peaks for known standards.

    Article Snippet: Minimum inhibitory concentration (MIC) values for both FLC (ThermoFisher; 86386-73-4) and MCF (MedChemExpress; 208538-73-2) were determined using the broth microdilution method ( ).

    Techniques: Gas Chromatography-Mass Spectrometry, In Vitro, Mutagenesis

    ERG3 mutants have a unique sterol profile consistent with Erg3 loss of function. ( A ) Mean relative abundance of sterols identified using targeted GC-MS after growth in the absence of antifungals or after growth + 0.5 µg/mL FLC. Mean value was calculated using three biological replicates per strain and per condition. See Table S6 for p-values. Asterisks indicate unidentified sterol that has similarity to Gramisterol. ( B ) Mean relative abundance of sterols identified using targeted GC-MS after growth in the absence of antifungals or after growth in 0.016 µg/mL MCF. Mean value was calculated using three biological replicates per strain and per condition. See Table S6 for p-values indicating significant differences in abundance of sterols. ( C ) Average response area of sterols without standards identified using GC-MS analysis after growth in the absence of antifungals or after growth + 0.016 µg/mL MCF or 0.5 µg/mL FLC. ( D ) Ergosterol biosynthesis pathway inferred from ( , , , ). Blue font indicates sterols synthesized as part of the alternative pathway, initiated following azole inhibition of Erg11. Biosynthetic steps where Erg3 functions are indicated in bold.

    Journal: bioRxiv

    Article Title: Micafungin exposure drives multidrug resistance in Clavispora lusitaniae

    doi: 10.64898/2026.06.29.735437

    Figure Lengend Snippet: ERG3 mutants have a unique sterol profile consistent with Erg3 loss of function. ( A ) Mean relative abundance of sterols identified using targeted GC-MS after growth in the absence of antifungals or after growth + 0.5 µg/mL FLC. Mean value was calculated using three biological replicates per strain and per condition. See Table S6 for p-values. Asterisks indicate unidentified sterol that has similarity to Gramisterol. ( B ) Mean relative abundance of sterols identified using targeted GC-MS after growth in the absence of antifungals or after growth in 0.016 µg/mL MCF. Mean value was calculated using three biological replicates per strain and per condition. See Table S6 for p-values indicating significant differences in abundance of sterols. ( C ) Average response area of sterols without standards identified using GC-MS analysis after growth in the absence of antifungals or after growth + 0.016 µg/mL MCF or 0.5 µg/mL FLC. ( D ) Ergosterol biosynthesis pathway inferred from ( , , , ). Blue font indicates sterols synthesized as part of the alternative pathway, initiated following azole inhibition of Erg11. Biosynthetic steps where Erg3 functions are indicated in bold.

    Article Snippet: Minimum inhibitory concentration (MIC) values for both FLC (ThermoFisher; 86386-73-4) and MCF (MedChemExpress; 208538-73-2) were determined using the broth microdilution method ( ).

    Techniques: Gas Chromatography-Mass Spectrometry, Synthesized, Inhibition

    Experimental observations of cancer cells distributed at low and high density (A and B) Breast cancer cell line MCF-7 at low and high density. (C and D) Breast cancer cell line MDA-MB-231 at low and high density. The scale bars on all panels represent 50 μm in length.

    Journal: iScience

    Article Title: Universal principles of cell population growth follow from local contact inhibition

    doi: 10.1016/j.isci.2026.115953

    Figure Lengend Snippet: Experimental observations of cancer cells distributed at low and high density (A and B) Breast cancer cell line MCF-7 at low and high density. (C and D) Breast cancer cell line MDA-MB-231 at low and high density. The scale bars on all panels represent 50 μm in length.

    Article Snippet: MCF-7 (human breast adenocarcinoma, female) , ATCC , RRID: CVCL_0031.

    Techniques: